Policy | August 03, 2022
PIB: Pharmaceutical industry in Maharashtra
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
Merck’s first microbiology application and training lab in India
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Company is investing more than €100 million in the expansion of the Halle site
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Subscribe To Our Newsletter & Stay Updated
